Immune Effector Cell Associated Neurotoxicity (ICANS) Among Pediatric and AYA Patients: MD Anderson Cancer Center Experience
Sign Up to like & getrecommendations! Published in 2020 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2019.12.397
Abstract: Introduction Immune effector cell associated neurotoxicity (ICANS) and cytokine release syndrome (CRS) are unique potentially life-threatening complications associated with immune effector cell (IEC) therapies. ICANS presents with varying symptoms ranging from confusion to seizure and… read more here.
Keywords: cell; aya patients; pediatric aya; immune effector ... See more keywords
Comprehensive care for Pediatric and AYA Sarcoma
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz341.001
Abstract: Abstract Advance in treatment strategies including surgery, radiation therapy and multiagent chemotherapy, the prognosis of Ewing sarcoma family of tumor (ESFT) and Rhabdomyosarcoma (RMS) has dramatically improved from the 1970’s in the United States and… read more here.
Keywords: sarcoma; care pediatric; pediatric aya; treatment ... See more keywords